Clinical evaluation of moxalactam.
Moxalactam was administered intravenously or intramuscularly or both in doses of 1 to 12 g/day to 45 patients with clinically significant infections (17 soft tissue or bone, 9 pleuropulmonary, 9 septicemic, 6 urinary tract, and 4 intraabdominal infections). Mean 0.5-h postinfusion levels were 105 mi...
Salvato in:
| Pubblicato in: | Antimicrob Agents Chemother |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society for Microbiology (ASM)
1982
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC182011/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6213198/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.21.5.780 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|